- US12582668utility2026Methods for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)0 cites
- US12582718utility2026Integrin Targeting Ligands and Uses Thereof0 cites
- US12534728utility2026Rnai Agents for Inhibiting Expression of 17beta-hsd Type 13 (HSD17B13), Compositions Thereof, and Methods of Use0 cites
- US12527877utility2026Anti-transferrin Receptor Antibodies, Conjugates Thereof, and Uses Thereof0 cites
- US12441756utility20255′-cyclo-phosphonate Modified Nucleotides0 cites
- US12365897utility2025Rnai Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use0 cites
- US12365899utility2025Rnai Agents and Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3)0 cites
- US12221610utility2025Rnai Agents for Inhibiting Expression of HIF-2 Alpha ( EPAS1 ), Compositions Thereof, and Methods of Use0 cites
- US12188017utility2025Compositions and Methods for Inhibiting Gene Expression of Alpha-1 Antitrypsin0 cites
- US12173086utility2024Alpha-v Beta-6 Integrin Ligands and Uses Thereof0 cites
- US12116573utility2024Targeting Ligands for Therapeutic Compounds0 cites
- US12091661utility2024Organic Compositions to Treat Hsf1-related Diseases0 cites
- US12065458utility2024Trialkyne Linking Agents and Methods of Use0 cites
- US12054718utility2024Rnai Agents for Inhibiting Expression of PNPLA3, Pharmaceutical Compositions Thereof, and Methods of Use0 cites
Page 1 of 2Next →